The role of urine prostate cancer antigen 3 mrna levels in the diagnosis of prostate cancer among hong kong chinese patients

Hong Kong Medical Journal

Volumn 18, Issue 6, 2012, Pages 459-465

  Ng, C F ^a   Chiu, P K F ^a   Lam, N Y ^a   Yeung, R ^b   Chow, J ^b   Chan, B ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Diagcor Bioscience Incorporation Limited   (Hong Kong)

Author keywords

Messenger; Predictive value of tests; Prostate specific antigen; Prostatic neoplasms; RNA; ROC curve

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HONG KONG; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POST PROSTATIC MASSAGE PROSTATE CANCER ANTIGEN 3 URINE LEVEL; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; URINALYSIS; URINE LEVEL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CHINA; CROSS-SECTIONAL STUDIES; DIGITAL RECTAL EXAMINATION; HONG KONG; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 84872175556     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-845.
2. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979.
3. van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-943.
4. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-1088.
5. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-1095.
6. Grasso M, Lania C, Blanco S, Baruffi M, Mocellin S. Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy. J Transl Med 2004;2:13.
7. Long N, Moore MA, Chen W, et al. Cancer epidemiology and control in north-East Asia-past, present and future. Asian Pac J Cancer Prev 2010;11(Suppl 2):107S-148S.
8. Ng CF, Ng MT, Yip KH. Urology update 2 - management of urol-oncology and associated urological symptoms. Hong Kong Pract 2009;31:128-132.
9. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 2008;101:675-683.
10. Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. J Urol 2007;178:2252-2259.
11. Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008;389:1-6.
12. Roobol MJ, Schroder FH, van Leeuwen P, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostatespecific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-481.
13. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology 2010;75:447-453.
14. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804-1809.
15. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-486.
16. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-315.